Repligen Corporation reports business developments as a global life sciences company focused on bioprocessing technologies and systems used in manufacturing biological drugs. Its updates center on Filtration and Fluid Management, Chromatography, Process Analytics and Proteins, serving biopharmaceutical drug developers, CDMOs and other life science customers.
Recurring announcements include quarterly and annual financial results, financial guidance, organic revenue measures, margin commentary, product and support infrastructure such as Repligen Training & Innovation Centers and OPUS pre-packed chromatography columns, investor conference participation, regional customer support initiatives and board or senior finance governance changes.
Repligen Corporation (NASDAQ:RGEN) will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference from January 10-13, 2022. CEO Tony J. Hunt is scheduled to present on January 12 at 9:45 a.m. EST. Investors can access a live webcast of the presentation on Repligen’s Investor Relations website, with a replay available for a limited time post-event. Repligen is a leader in developing innovative bioprocessing technologies that enhance the manufacturing of biological drugs, serving biopharmaceutical developers and CDMOs globally.
Repligen Corporation (NASDAQ:RGEN) announced its participation in two investor conferences. The first is Stifel’s 2021 Virtual Healthcare Conference from November 15-17, where CEO Tony J. Hunt will hold a fireside chat on November 17 at 8:00 a.m. EST. The second is the Stephens Annual Investment Conference from December 1-3, featuring CFO Jon K. Snodgres on December 3 at 11:00 a.m. EST. Live webcasts will be accessible through the Investor Relations section of the company’s website, with replays available thereafter.
Summary not available.
Repligen Corporation (NASDAQ:RGEN) reported record revenue of $178.2 million for Q3 2021, reflecting an 89% year-over-year growth and 77% organic growth. The company raised its full-year revenue guidance to $655-$665 million. Key highlights include a 49% organic growth from its base business and significant contributions from COVID-related sales, which rose 247%. The gross margin improved to 58.3%, and the fully diluted EPS increased to $0.58. The positive trajectory is attributed to strategic acquisitions and growth in gene therapy revenue.
Repligen Corporation (NASDAQ:RGEN) will release its third quarter 2021 financial results on October 28, 2021, prior to market open. A conference call will follow at 8:30 a.m. EDT to discuss business updates and results for the three- and nine-month periods ending September 30, 2021. Interested parties can access the call by dialing specific numbers based on their location. Repligen, a life sciences company, focuses on innovative bioprocessing technologies for biopharmaceutical manufacturers globally. More details can be found on their website.
Repligen Corporation (NASDAQ:RGEN) has entered into a definitive agreement to acquire Avitide Inc. for approximately $150 million. The deal includes $75 million in cash and $75 million in Repligen common stock, alongside performance-based earnouts over three years. This acquisition aims to enhance Repligen’s Proteins business, particularly in affinity ligand solutions for gene therapy, with Avitide expected to contribute about $10 million in revenue in 2022 and positively impact adjusted earnings per share in 2023.
Repligen Corporation (NASDAQ:RGEN) and Navigo Proteins GmbH announced the successful development of a novel protein A ligand called NGL-Impact A Hi pH. This innovative ligand addresses critical challenges in purifying pH sensitive antibodies and Fc-fusion proteins, notably reducing antibody aggregation during purification. Customer evaluations showcased a two-fold decrease in aggregate formation while maintaining high dynamic binding capacity. The ligand is set for commercialization via a new resin later this year, potentially offering significant cost and time savings for developers in the biopharmaceutical industry.
Repligen Corporation (NASDAQ:RGEN) reported Q2 2021 revenue of $163.0 million, achieving an 86% year-over-year growth and 69% organic growth. The company raised its revenue guidance for 2021 to $625-$645 million from previous estimates of $565-$590 million. The acquisition of Polymem S.A. further enhances Repligen's capabilities. Key financial metrics include a GAAP EPS of $0.64 and adjusted EPS of $0.79 for the quarter. The company anticipates a gross margin of 59%-60% for the year, reflecting ongoing strong performance.
Repligen Corporation (NASDAQ:RGEN) will report its Q2 2021 financial results on July 27, 2021. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. EDT to discuss financial results for the three- and six-month periods ending June 30, 2021. Domestic callers can dial (844) 274-3999, while international callers can use (412) 317-5607. The call will also be available via a webcast on the company’s Investor Relations webpage, with archived access provided as well.
Repligen Corporation (NASDAQ:RGEN) announced its acquisition of Polymem S.A., a French specialist in hollow fiber membranes, on June 22, 2021. This acquisition enhances Repligen's production capabilities and R&D expertise, positioning it to meet growing demand in both industrial and bioprocessing markets. The deal is expected to close in Repligen's third fiscal quarter of 2021, utilizing cash reserves of approximately $711 million as of March 31, 2021. Polymem's leadership will remain in place post-acquisition, aiming to expand market reach and growth opportunities.